Cancer institute backed by Larry Ellison plans major layoffs in Los Angeles
This is read by an automated voice.Please report any issues or inconsistencies here.
See more from the L.A.Times in Google Search.
Set us as preferred The Ellison Medical Institute — a cancer research center funded by tech mogul Larry Ellison — will cut a chunk of its staff in a couple of months.The Los Angeles-based research center, led by its founding chief executive and oncologist, David Agus, plans to permanently lay off 88 employees in January, according to a Worker Adjustment and Retraining Notification filed Nov.
4.The institute describes itself as a medical research and development center focused on artificial intelligence, molecular analytics and interdisciplinary disease research and treatment, with preventative medicine and cancer clinics, research laboratories and community education programs.The 84,000-square-foot institute is at 12414 Exposition Blvd., near the Expo/Bundy Metro station.Its LinkedIn company profile lists it as having 51 to 200 employees.The Ellison Medical Institute did not respond to requests for comment on the reasons for the layoffs.Ellison has long focused on cancer research and has made substantial donations to the cause.
California Oracle founder Larry Ellison never finished college, much less attended USC.In his Oracle AI World 2026 keynote speech, Ellison said AI will make most cancers “gone in five years, and certainly in 10.”In 2016, Ellison donated $200 million to USC to build the interdisciplinary medical center focused on cancer.
The Lawrence J.Ellison Institute for Transformative Medicine of USC was meant to combine research with the holistic prevention and treatment of cancer.
It later moved from USC..The institute has also been active in drug development.
In June, it signed an exclusive license with UniQuest, the commercialization company of the University of Queensland in Australia, to advance a new prostate cancer treatment.The drug could reach first-in-human trials as early as 2027, according t...